First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells
Movement Disorders · 2023
DOI: 10.1002/mds.29316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders, 2023. Verfasst von Joopyoung Kim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Parkinson Disease, Neural Stem Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Because human fetal ventral mesencephalic tissue grafts provide promising results in ameliorating Parkinson's disease–implicated motor dysfunctions, human fetal midbrain‐derived dopamine neuronal precursor cells are considered good candidates for cell‐based therapy for Parkinson's disease in that large quantities of cells can be supplied through a good manufacturing practice–compliant system.
Objective
We conducted a prospective, phase I/IIa, dose‐escalation, open‐label “first‐in‐human” clinical trial with fetal neural precursor cells to assess their safety and therapeutic efficacy in patients with idiopathic Parkinson's disease.
Methods
Fifteen patients were assigned to receive three different doses of cells (4 × 10 6 , 12 × 10 6 , and 40 × 10 6 cells) and completed a 12‐month follow‐up. The primary outcome was safety, by measuring the presence of grade 3 or higher cells according to National Cancer Institute guidelines and any contaminated cells. Secondary outcomes assessed motor and neurocognitive function, as well as the level of dopamine transporters, by positron emission tomography–computed tomography.
Results
Although a pronation‐supination and hand/arm movement performance was remarkably enhanced in all three groups (all P < 0.05), the medium‐ and high‐dose‐treated groups exhibited significant improvement in Unified Parkinson's Disease Rating Scale Part III only up to 26.16% and 40%, respectively, at 12 months after transplantation without any serious clinical complications or graft‐induced dyskinesia in all patients. However, the motor improvements did not correlate with increase in the dopamine transporter on positron emission tomography images.
Conclusions
Our results primarily demonstrate the safety and plausible dose‐dependent efficacy of human fetal midbrain‐derived dopamine neuronal precursor cells for idiopathic Parkinson's disease. © 2023 International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
- Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
- Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
- Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
- Department of Neuroradiology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.
- Department of Biotechnology, CHA University, Seongnam, Republic of Korea.
ORCID-Profile: Jisook Moon
Zitieren
APA
Kim, J., Inbo, H., Kim, H. S., Kim, W., Jang, S. J., Min, K., Kim, S. H., Bae, S. H., Jeong, Y. H., Kim, B., Kim, C., Schwarz, S. C., Schwarz, J., Cho, K. G., Chung, S. S., & Moon, J. (2023). First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells. Movement Disorders. https://doi.org/10.1002/mds.29316
Vancouver
Kim J, Inbo H, Kim HS, Kim W, Jang SJ, Min K, et al. First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells. Movement Disorders. 2023. doi:10.1002/mds.29316
BibTeX
@article{Kim2023,
author = {Kim, Joopyoung and Inbo, Han and Kim, Hyun Sook and Kim, WonChan and Jang, Su Jin and Min, Kyunghoon and Kim, Sang Heum and Bae, Sang-Hun and Jeong, Yun-Hwa and Kim, Borah and Kim, Chul and Schwarz, Sigrid C and Schwarz, Johannes and Cho, Kyung Gi and Chung, Sang-Sup and Moon, Jisook},
title = {First Clinical Report on the Treatment of Parkinson's Disease with Fetal Midbrain Precursor Cells},
journal = {Movement Disorders},
year = {2023},
doi = {10.1002/mds.29316}
}
EUVIMED